



# Scope

---

- Pre-clinical research
  - New or repurposed drugs, biologics, devices
  - Neuroprotection, regeneration, plasticity
- In vitro/In vivo
- Assay development
- POC in SCI injury models
- Dose, timing, non-GLP toxicology, PK/PD, biomarker development
- Medical devices in similar pre-clinical stages
- Phenotypic drug development/targets **if** mechanistic rationale provided

**Out of scope:**  
Clinical Research  
Full drug screens  
IND/IDE enabling studies

# Eligibility, Funding

---

- Eligibility

- Terminal degree beyond Post Doctoral level at time of full grant application
- Academia, industry (partnerships encouraged), global
- One application per Primary Investigator (permanent position at institution)/lab

- Funding

- 1-2 years
- Up to \$250,000 (budget in USD), 10% cap on indirects
- Subcontracts to CROs allowed and encouraged where needed expertise not available (NIH Blueprint website)

# Data Sharing, IP

---

- Data Sharing/Publication
  - Open data sharing of non-intellectual property required
    - Data management plan will be required in full grant application
  - Any repository using FAIR principles
  - ODC-SCI (<https://odc-sci.org/>)- NIH supported data sharing resource
  - Open access publications encouraged
  
- IP
  - Held by applicant/institution

# Process

---

- Two stage
  - Letter of intent (LOI)
  - Full grant application (FGA)
  - Milestone driven
- LOI due: December 12, 5:00 pm ET
- FGA invitations: January 2025
- FGA due: March 2025
- Anticipated award announcements: June 2025
- Anticipated funding: August 2025

# Process/Application

---

- Impact
  - For people living with SCI
  - On field
- Indication
  - Neuroprotection, regeneration, plasticity
  - Target population: acuity, severity, level of SCI (if known)
- Therapeutic
  - Type, mode of action, how identified, strengths and challenges
- Target
  - Biological target, MOA and pathway, evidence of target engagement if available
- Stage of Development
  - Current stage, relevant data justifying next stage, Therapeutic Template Profile (optional)
- Development Plan
  - Describe research plan, how will this contribute towards developing a therapeutic for PwSCI

# LOI Review Criteria

---

- Impact
  - For people living with SCI and the field
- Target viability
  - Supportive rationale/evidence for target in SCI
- Stage of Development
  - Understanding of drug development pathway, gaps, next steps
- Development Plan
  - Research plan appropriate for development stage and feasible
- Intellectual Property
  - Barriers?
- Team
  - Appropriate knowledge and ability to execute next drug development stage

# Therapeutic Template Profile

---

## DEVELOPMENT STAGE

Hit-to-lead     Lead Optimization     Non-GLP toxicity     Repositioned / Repurposed

## DRUG-TARGET RELATIONSHIP


- SELECTIVITY
- IN VITRO POTENCY
  - ASSAY UTILIZED
- CELLULAR POTENCY
  - ASSAY UTILIZED
  - THERAPEUTIC CHARACTERISTICS
- IS THERE A PK/PD RELATIONSHIP?
- ADDITIONAL PK INFORMATION :
  - Dose(s), Route(s) of Administration (if known), species, tissues (i.e. spinal cord, CSF, plasma, time points tested)
- TARGET ENGAGEMENT MARKERS SELECTED



# Online Platform- Foundant

## Reeve Foundation online grants portal

administrator@grantinterface.com



- Each applicant should create their own account regardless of institution. Multiple applicants may apply from the same institution, just not the same lab/company.
- You can abandon your request, save, or submit LOI. You will receive an automated email from the grant portal confirming your submission has been received. Keep in mind the close date is December 12, 5:00 p.m. Eastern Time.
- Registration/Foundant Assistance at [FoundantHelp@reeve.org](mailto:FoundantHelp@reeve.org).

# Key Deadlines

---

- LOI due: December 12, 5:00 pm ET
- FGA invitations: January 2025
- FGA due: March 2025
- Anticipated award announcements: June 2025
- Anticipated funding: August 2025
  
- Questions
  - Foundant/process: Maria Fonseca (FoundantHelp@Reeve.org)
  - Application scope: Linda Jones (ljones@Reeve.org)

**Read the Application  
Guide**

On Reeve website and link  
to PDF in Foundant